BMJ:习惯性葡萄糖胺使用与心血管疾病风险的关联

2019-05-16 xing.T 网络

由此可见,习惯性使用葡萄糖胺补充剂来缓解骨关节炎疼痛,也可能与降低CVD事件的风险有关。

近日,顶级杂志BMJ上发表了一篇研究文章,研究人员旨在前瞻性地评估习惯性葡萄糖胺使用与血管疾病(CVD)事件风险之间的关系。

该研究为前瞻性队列研究,以英国生物银行为基础。466039名基线没有CVD的参与者完成了补充剂使用问卷,其中包括葡萄糖胺。这些参与者从2006年到2010年注册,一直随访到2016年。该研究的主要结果指标为CVD事件,包括血管疾病死亡、冠心病和卒中。 

在中位随访7年期间,发生了10204例CVD事件,3060例CVD死亡,5745例冠心病事件和3263例卒中事件。在调整年龄、性别、体重指数、种族、生活方式因素、膳食摄入量、药物使用和其他补充剂使用后,葡萄糖胺的使用与总CVD事件(风险比为0.85,95%置信区间为0.80 至0.90)、CVD死亡(0.78,0.70至0.87)、冠心病(0.82,0.76至0.88)和卒中(0.91,0.83至1.00)的风险显著降低相关。 

由此可见,习惯性使用葡萄糖胺补充剂来缓解骨关节炎疼痛,也可能与降低CVD事件的风险有关。 

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734971, encodeId=e4e41e34971c3, content=<a href='/topic/show?id=532688266d4' target=_blank style='color:#2F92EE;'>#葡萄糖胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88266, encryptionId=532688266d4, topicName=葡萄糖胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a5433851080, createdName=xiaogang328, createdTime=Sun Jun 02 12:27:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848747, encodeId=0f7b1848e47a1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Dec 09 15:27:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473173, encodeId=a64014e3173f5, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498571, encodeId=974b14985e163, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734971, encodeId=e4e41e34971c3, content=<a href='/topic/show?id=532688266d4' target=_blank style='color:#2F92EE;'>#葡萄糖胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88266, encryptionId=532688266d4, topicName=葡萄糖胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a5433851080, createdName=xiaogang328, createdTime=Sun Jun 02 12:27:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848747, encodeId=0f7b1848e47a1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Dec 09 15:27:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473173, encodeId=a64014e3173f5, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498571, encodeId=974b14985e163, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-12-09 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734971, encodeId=e4e41e34971c3, content=<a href='/topic/show?id=532688266d4' target=_blank style='color:#2F92EE;'>#葡萄糖胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88266, encryptionId=532688266d4, topicName=葡萄糖胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a5433851080, createdName=xiaogang328, createdTime=Sun Jun 02 12:27:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848747, encodeId=0f7b1848e47a1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Dec 09 15:27:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473173, encodeId=a64014e3173f5, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498571, encodeId=974b14985e163, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734971, encodeId=e4e41e34971c3, content=<a href='/topic/show?id=532688266d4' target=_blank style='color:#2F92EE;'>#葡萄糖胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88266, encryptionId=532688266d4, topicName=葡萄糖胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a5433851080, createdName=xiaogang328, createdTime=Sun Jun 02 12:27:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848747, encodeId=0f7b1848e47a1, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Dec 09 15:27:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473173, encodeId=a64014e3173f5, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498571, encodeId=974b14985e163, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri May 17 23:27:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]

相关资讯

Arthritis Res Ther:葡萄糖胺联合双醋瑞因治疗并不能改善骨关节炎患者的症状

据发表于 Arthritis Res Ther的一项新的研究显示,与葡萄糖胺单药治疗相比,葡萄糖胺联合双醋瑞因治疗并不能改善疼痛评分。葡萄糖胺具有合成代谢的作用,而双醋瑞因具有分解代谢的作用,因此研究人员推测联合两种药物治疗或较单药治疗能更好的改善患者的疼痛和功能。为了验证这一假设,研究人员进行了一项双盲,平行,随机对照试验,研究共纳入了148名(平均年龄为60岁)轻度到中度的膝骨关节炎